Astria Therapeutics, Inc. (ATXS)
After hours:
| Previous close | 10.54 |
| Open | 10.42 |
| Bid | 9.70 x 100 |
| Ask | 9.77 x 200 |
| Day's range | 9.48 - 10.64 |
| 52-week range | 4.26 - 16.90 |
| Volume | |
| Avg. volume | 1,046,171 |
| Market cap | 535.305M |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.42 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 24.57 |
Business WireAstria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
BOSTON, April 09, 2024--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience.
GuruFocus.comChief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)
Astria Therapeutics Inc (NASDAQ:ATXS), a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat debilitating diseases, has reported an insider sale according to a recent SEC filing.
Business WireAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 03, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 9,000 shares of Astria’s common stock on April 1, 2024 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.
